Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in T2DM and IGT
NCT01068860Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2010
- Primary completion
- Aug 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of canakinumab in type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), sponsored by Novartis. Started Feb 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
type 2 diabetes mellitus (T2DM)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT01068860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068860.